Hey @singhgu, the indication I was referring to is the COVID related trials
Those are the outsourced trials that I wouldnt hold my breath on
They need funding (either from partnership or CR) for kidney trials which I am agreeing would improve the SP
TBH, this will be unpopular, but the FSGS results are not very strong. 7 patients whose average response is likely driven by 1 or 2 patients based on the individual patient data shown thus far
DKD sub analysis communication has gone silent. The last couple decks have shed almost no light on a data-based explanation for why the placebo group performed well. so make of that what you will.
good luck.
Hey @singhgu, the indication I was referring to is the COVID...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.015(4.48%) |
Mkt cap ! $175.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 31.5¢ | $1.333M | 4.143M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 727594 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 170412 | 4 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
32.0¢ |
Change
-0.015 ( 3.15 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 33.5¢ | 31.5¢ | 2261030 | ||
| Last updated 15.51pm 26/04/2024 ? | |||||
| DXB (ASX) Chart |